✦ LIBER ✦

Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: A randomized open label trial

✍ Scribed by Dr Moon Yong Chung; Kyung Ho Min; Yong Ju Jun; Sung Soo Kim; Wan Chul Kim; Eun Mi Jun

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 88 KB
Volume: 19
Category: Article
ISSN: 0885-6222
DOI: 10.1002/hup.615

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

The aim of this study was to investigate the potential use of mirtazapine in Korean veterans diagnosed with PTSD, by comparing it with sertraline, a drug approved for use in PTSD in the USA.

Methods

Efficacy was evaluated by the clinician administered PTSD scale (CAPS‐2), the Hamilton rating scale for depression (HAMD‐17) and the clinical global impression scale (CGI), at baseline and at weeks 1, 2 and 6. A response was defined as a ≥ 30 % decrease in CAPS‐2 total severity, a ≥ 50 % decrease in total HAMD‐17 score, and a CGI‐I score < 3.

Results

51 patients on mirtazapine (mean age/duration of illness: 59.1/33.5 years) and 49 on sertraline (mean age/duration of illness: 60.6/35.6 years) completed the study. The mean daily dosage was 34.1 mg for mirtazapine and 101.5 mg for sertraline. On the CAPS‐2 total score more patients responded in the mirtazapine group at week 1 (13 vs 2 %) and week 2 (51 vs 31 %). At week 6 this difference was statistically significant (88 % vs 69 %, p = 0.039) on the CAPS‐2 total score. The HAMD‐17 total score and CGI‐I score decreased in both groups, with no significant differences between th groups on all time points. The main side effects for the mirtazapine group were: dry mouth (19.6 %), constipation (19.6 %), somnolence (15.7 %) and weight gain (1.96 %); and for the sertraline group: indigestion (14.3 %), palpitation (6.1 %), agitation (2.0 %), epigastric soreness (2.0 %), insomnia (2.0 %) and sexual dysfunction (2.0 %).

Conclusion

📜 SIMILAR VOLUMES

Safety and efficacy of long-acting injec

Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: A 6-month open-label trial in Asian patients

✍ Swapna Verma; Mythily Subramaniam; Edimansyah Abdin; Kang Sim; Alex Su; Nelson L 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

## Abstract The study aimed to evaluate the efficacy of long‐acting injectable risperidone (LAR) in Asian patients with schizophrenia spectrum disorders. Twenty‐five patients enrolled in this 6‐month open labelled study. They were switched from their current antipsychotic to LAR without a prior or